p53 antibody: is it an indicator of dedifferentiated thyroid cancer?


HASBEK Z. , TURGUT B. , ERSELCAN T.

ANNALS OF NUCLEAR MEDICINE, cilt.28, ss.42-46, 2014 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 28 Konu: 1
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1007/s12149-013-0783-8
  • Dergi Adı: ANNALS OF NUCLEAR MEDICINE
  • Sayfa Sayıları: ss.42-46

Özet

Radioiodine is the most effective treatment modality in differentiated thyroid carcinoma, either in metastatic or residual thyroid tissue. However, sometimes dedifferentiation can develop and the effectiveness of radioactive I-131 decreases. The p53 is a tumor suppressor gene which plays an important role in controlling normal cell proliferation regulation. In the serum of healthy individuals, the presence of p53 autoantibodies is extremely rare. Mutations in this gene cause an accumulation of non-functional proteins and may lead to development of anti-p53 antibodies. The aim of the present study was to devise a simple blood test that could lead to early identification of patients with dedifferentiation. In this respect, we investigate whether the serum level of anti-p53 antibody is of diagnostic value in the follow-up of patients with high levels of thyroglobulin (Tg) and negative I-131 scan.